-
1
-
-
76849086881
-
Targeting B cells in immune-mediated infammatory disease: A comprehensive review of mechanisms of action and identifcation of biomarkers
-
Dorner T, Kinnman N, Tak PP. Targeting B cells in immune-mediated infammatory disease: a comprehensive review of mechanisms of action and identifcation of biomarkers. Pharmacol. Ther. 125(3), 464-475 (2010).
-
(2010)
Pharmacol. Ther.
, vol.125
, Issue.3
, pp. 464-475
-
-
Dorner, T.1
Kinnman, N.2
Tak, P.P.3
-
2
-
-
2942537697
-
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
-
DOI 10.1056/NEJMoa032534
-
Edwards JC, Szczepanski L, Szechinski J et al. Effcacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350(25), 2572-2581 (2004). (Pubitemid 38758544)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.25
, pp. 2572-2581
-
-
Edwards, J.C.W.1
Szczepanski, L.2
Szechinski, J.3
Filipowicz-Sosnowska, A.4
Emery, P.5
Close, D.R.6
Stevens, R.M.7
Shaw, T.8
-
3
-
-
38149065192
-
Updates from B cell trials: Effcacy
-
Cohen SB. Updates from B cell trials: effcacy. J. Rheumatol. Suppl. 77, 12-17 (2006).
-
(2006)
J. Rheumatol. Suppl.
, vol.77
, pp. 12-17
-
-
Cohen, S.B.1
-
4
-
-
77953715791
-
Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate
-
Cohen SB, Keystone E, Genovese MC et al. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. Ann. Rheum. Dis. 69(6), 1158-1161 (2010).
-
(2010)
Ann. Rheum. Dis.
, vol.69
, Issue.6
, pp. 1158-1161
-
-
Cohen, S.B.1
Keystone, E.2
Genovese, M.C.3
-
5
-
-
37149035531
-
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis
-
DOI 10.1002/art.23059
-
Keystone E, Fleischmann R, Emery P et al. Safety and effcacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 56(12), 3896-3908 (2007). (Pubitemid 350262316)
-
(2007)
Arthritis and Rheumatism
, vol.56
, Issue.12
, pp. 3896-3908
-
-
Keystone, E.1
Fleischmann, R.2
Emery, P.3
Furst, D.E.4
Van Vollenhoven, R.5
Bathon, J.6
Dougados, M.7
Baldassare, A.8
Ferraccioli, G.9
Chubick, A.10
Udell, J.11
Cravets, M.W.12
Agarwal, S.13
Cooper, S.14
Magrini, F.15
-
6
-
-
82755176118
-
Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: The RESET trial
-
Haraoui B, Bokarewa M, Kallmeyer I, Bykerk V P. Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET trial. J. Rheumatol. 38(12), 2548-2556 (2011).
-
(2011)
J. Rheumatol.
, vol.38
, Issue.12
, pp. 2548-2556
-
-
Haraoui, B.1
Bokarewa, M.2
Kallmeyer, I.3
Bykerk, V.P.4
-
7
-
-
34548249142
-
Repeated B-cell depletion in clinical practice [5]
-
DOI 10.1093/rheumatology/kem164
-
Edwards JC, Cambridge G, Leandro MJ. Repeated B-cell depletion in clinical practice. Rheumatology (Oxf.) 46(9), 1509 (2007). (Pubitemid 47321579)
-
(2007)
Rheumatology
, vol.46
, Issue.9
, pp. 1509
-
-
Edwards, J.C.W.1
Cambridge, G.2
Leandro, M.J.3
-
8
-
-
27544508559
-
Tolerability and safety of rituximab (MabThera)
-
Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat. Rev. 31(6), 456-473 (2005).
-
(2005)
Cancer Treat. Rev.
, vol.31
, Issue.6
, pp. 456-473
-
-
Kimby, E.1
-
9
-
-
45349102781
-
Anti-CD20 therapy in patients with rheumatoid arthritis: Predictors of response and b cell subset regeneration after repeated treatment
-
DOI 10.1002/art.23473
-
Roll P, Dorner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum. 58(6), 1566-1575 (2008). (Pubitemid 351847509)
-
(2008)
Arthritis and Rheumatism
, vol.58
, Issue.6
, pp. 1566-1575
-
-
Roll, P.1
Dorner, T.2
Tony, H.-P.3
-
10
-
-
82555190963
-
Effect of rituximab on human in vivo antibody immune responses
-
Pescovitz MD, Torgerson TR, Ochs HD et al. Effect of rituximab on human in vivo antibody immune responses. J. Allergy Clin. Immunol. 128(6), 1295-1302 (2011).
-
(2011)
J. Allergy Clin. Immunol.
, vol.128
, Issue.6
, pp. 1295-1302
-
-
Pescovitz, M.D.1
Torgerson, T.R.2
Ochs, H.D.3
-
11
-
-
79958071035
-
The anti-CD20 antibody rituximab reduces the Th17 cell response
-
van de Veerdonk FL, Lauwerys B, Marijnissen RJ et al. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum. 63(6), 1507-1516 (2011).
-
(2011)
Arthritis Rheum.
, vol.63
, Issue.6
, pp. 1507-1516
-
-
Van De Veerdonk, F.L.1
Lauwerys, B.2
Marijnissen, R.J.3
-
12
-
-
68849127971
-
Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: Consistency across centers
-
Bresnihan B, Pontifex E, Thurlings RM et al. Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers. J. Rheumatol. 36(8), 1800-1802 (2009).
-
(2009)
J. Rheumatol.
, vol.36
, Issue.8
, pp. 1800-1802
-
-
Bresnihan, B.1
Pontifex, E.2
Thurlings, R.M.3
-
13
-
-
33947102642
-
Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis
-
DOI 10.1002/art.22400
-
Vos K, Thurlings RM, Wijbrandts CA, van Schaardenburg D, Gerlag DM, Tak PP. Early effects of rituximab on the synovial cell infltrate in patients with rheumatoid arthritis. Arthritis Rheum. 56(3), 772-778 (2007). (Pubitemid 46399424)
-
(2007)
Arthritis and Rheumatism
, vol.56
, Issue.3
, pp. 772-778
-
-
Vos, K.1
Thurlings, R.M.2
Wijbrandts, C.A.3
Van Schaardenburg, D.4
Gerlag, D.M.5
Tak, P.P.6
-
14
-
-
79959832697
-
Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: Results of a Phase 2, randomized, placebo-controlled, dose-fnding trial
-
Genovese MC, Kinnman N, de La Bourdonnaye G, Pena Rossi C, Tak PP. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a Phase 2, randomized, placebo-controlled, dose-fnding trial. Arthritis Rheum. 63(7), 1793-1803 (2011).
-
(2011)
Arthritis Rheum.
, vol.63
, Issue.7
, pp. 1793-1803
-
-
Genovese, M.C.1
Kinnman, N.2
De La Bourdonnaye, G.3
Pena Rossi, C.4
Tak, P.P.5
-
15
-
-
3542999932
-
Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses
-
DOI 10.1111/j.1600-6143.2004.00502.x
-
Agarwal A, Vieira CA, Book BK, Sidner RA, Fineberg NS, Pescovitz MD. Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses. Am. J. Transplant. 4(8), 1357-1360 (2004). (Pubitemid 39013585)
-
(2004)
American Journal of Transplantation
, vol.4
, Issue.8
, pp. 1357-1360
-
-
Agarwal, A.1
Vieira, C.A.2
Book, B.K.3
Sidner, R.A.4
Fineberg, N.S.5
Pescovitz, M.D.6
-
16
-
-
73249114021
-
Suppressive functions of activated B cells in autoimmune diseases reveal the dual roles of Toll-like receptors in immunity Immunol
-
Lampropoulou V, Calderon-Gomez E, Roch T et al. Suppressive functions of activated B cells in autoimmune diseases reveal the dual roles of Toll-like receptors in immunity Immunol. Rev. 233(1), 146-161 (2010).
-
(2010)
Rev.
, vol.233
, Issue.1
, pp. 146-161
-
-
Lampropoulou, V.1
Calderon-Gomez, E.2
Roch, T.3
-
17
-
-
83455169104
-
+ cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjects
-
+ cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjects. Arthritis Res. Ther. 13(6), R208 (2011).
-
(2011)
Arthritis Res. Ther.
, vol.13
, Issue.6
-
-
Eggleton, P.1
Bremer, E.2
Tarr, J.M.3
-
19
-
-
67349120767
-
Long term treatment of rheumatoid arthritis with rituximab
-
Caporali R, Caprioli M, Bobbio-Pallavicini F, Bugatti S, Montecucco C. Long term treatment of rheumatoid arthritis with rituximab. Autoimmun. Rev. 8(7), 591-594 (2009).
-
(2009)
Autoimmun. Rev.
, vol.8
, Issue.7
, pp. 591-594
-
-
Caporali, R.1
Caprioli, M.2
Bobbio-Pallavicini, F.3
Bugatti, S.4
Montecucco, C.5
-
20
-
-
79955806071
-
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
-
Buch MH, Smolen JS, Betteridge N et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 70(6), 909-920 (2011).
-
(2011)
Ann. Rheum. Dis.
, vol.70
, Issue.6
, pp. 909-920
-
-
Buch, M.H.1
Smolen, J.S.2
Betteridge, N.3
-
21
-
-
82355169068
-
Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: A retrospective pooled analysis
-
Emery P, Mease PJ, Rubbert-Roth A et al. Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis. Rheumatology (Oxf.) 50(12), 2223-2232 (2011).
-
(2011)
Rheumatology (Oxf.)
, vol.50
, Issue.12
, pp. 2223-2232
-
-
Emery, P.1
Mease, P.J.2
Rubbert-Roth, A.3
-
22
-
-
77951830908
-
Effects of early rituximab retreatment in rheumatoid arthritis patients with an inadequate response after the frst cycle: Retrospective arthritis cohort study
-
Bastian H, Zinke S, Egerer K et al. Effects of early rituximab retreatment in rheumatoid arthritis patients with an inadequate response after the frst cycle: retrospective arthritis cohort study. J. Rheumatol. 37(5), 1069-1071 (2010).
-
(2010)
J. Rheumatol.
, vol.37
, Issue.5
, pp. 1069-1071
-
-
Bastian, H.1
Zinke, S.2
Egerer, K.3
-
23
-
-
34047142747
-
Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs
-
DOI 10.1093/rheumatology/kel393
-
Popa C, Leandro MJ, Cambridge G, Edwards JC. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 years. Rheumatology (Oxf.) 46(4), 626-630 (2007). (Pubitemid 46523308)
-
(2007)
Rheumatology
, vol.46
, Issue.4
, pp. 626-630
-
-
Popa, C.1
Leandro, M.J.2
Cambridge, G.3
Edwards, J.C.W.4
-
24
-
-
84857238940
-
Biological treatment of rheumatoid arthritis: Towards a more cost-effective re-treatment regimen using rituximab?
-
Boumans MJ, Vos K, Gerlag DM, Tak PP. Biological treatment of rheumatoid arthritis: towards a more cost-effective re-treatment regimen using rituximab? Ann. Rheum. Dis. 71(3), 472-473 (2012).
-
(2012)
Ann. Rheum. Dis.
, vol.71
, Issue.3
, pp. 472-473
-
-
Boumans, M.J.1
Vos, K.2
Gerlag, D.M.3
Tak, P.P.4
-
25
-
-
70049108310
-
Short-and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis
-
Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M. Short-and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res. Ther. 11(4), R123 (2009).
-
(2009)
Arthritis Res. Ther.
, vol.11
, Issue.4
-
-
Rehnberg, M.1
Amu, S.2
Tarkowski, A.3
Bokarewa, M.I.4
Brisslert, M.5
-
26
-
-
77953367640
-
hi) B cells in infamed lymph nodes are associated with the onset of infammatory-erosive arthritis in TNF-transgenic mice and are targets of anti-CD20 therapy
-
hi) B cells in infamed lymph nodes are associated with the onset of infammatory-erosive arthritis in TNF-transgenic mice and are targets of anti-CD20 therapy. J. Immunol. 184(11), 6142-6150 (2010).
-
(2010)
J. Immunol.
, vol.184
, Issue.11
, pp. 6142-6150
-
-
Li, J.1
Kuzin, I.2
Moshkani, S.3
-
27
-
-
77956158598
-
Targeting the B cell in rheumatoid arthritis
-
Cohen SB. Targeting the B cell in rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 24(4), 553-563 (2010).
-
(2010)
Best Pract. Res. Clin. Rheumatol.
, vol.24
, Issue.4
, pp. 553-563
-
-
Cohen, S.B.1
-
28
-
-
70049095511
-
Long-term effects of rituximab in rheumatoid arthritis: Clinical, biologic, and pharmacogenetic aspects
-
Quartuccio L, Lombardi S, Fabris M et al. Long-term effects of rituximab in rheumatoid arthritis: clinical, biologic, and pharmacogenetic aspects. Ann. NY Acad. Sci. 1173, 692-700 (2009).
-
(2009)
Ann. NY Acad. Sci.
, vol.1173
, pp. 692-700
-
-
Quartuccio, L.1
Lombardi, S.2
Fabris, M.3
-
29
-
-
77949673916
-
Long term safety of patients receiving rituximab in rheumatoid arthritis clinical trials
-
van Vollenhoven RF, Emery P, Bingham CO 3rd et al. Long term safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J. Rheumatol. 37(3), 558-567 (2010).
-
(2010)
J. Rheumatol.
, vol.37
, Issue.3
, pp. 558-567
-
-
Van Vollenhoven, R.F.1
Emery, P.2
Bingham III, C.O.3
-
30
-
-
33747338728
-
Tumor necrosis factor inhibitors for rheumatoid arthritis
-
Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N. Engl. J. Med. 355(7), 704-712 (2006).
-
(2006)
N. Engl. J. Med.
, vol.355
, Issue.7
, pp. 704-712
-
-
Scott, D.L.1
Kingsley, G.H.2
-
31
-
-
78650908659
-
Does rituximab increase the incidence of infectious complications? A narrative review
-
Kelesidis T, Daikos G, Boumpas D, Tsiodras S. Does rituximab increase the incidence of infectious complications? A narrative review. Int. J. Infect. Dis. 15(1), e2-e16 (2011).
-
(2011)
Int. J. Infect. Dis.
, vol.15
, Issue.1
-
-
Kelesidis, T.1
Daikos, G.2
Boumpas, D.3
Tsiodras, S.4
-
32
-
-
77956391149
-
Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry
-
Gottenberg JE, Ravaud P, Bardin T et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry Arthritis Rheum. 62(9), 2625-2632 (2010).
-
(2010)
Arthritis Rheum.
, vol.62
, Issue.9
, pp. 2625-2632
-
-
Gottenberg, J.E.1
Ravaud, P.2
Bardin, T.3
-
33
-
-
77949570681
-
Safety of rituximab in rheumatoid arthritis patients with a history of severe or recurrent bacterial infection: Observational study of 30 cases in everyday practice
-
Toussirot E, Pertuiset E, Sordet C et al. Safety of rituximab in rheumatoid arthritis patients with a history of severe or recurrent bacterial infection: observational study of 30 cases in everyday practice. Joint Bone Spine 77(2), 142-145 (2010).
-
(2010)
Joint Bone Spine
, vol.77
, Issue.2
, pp. 142-145
-
-
Toussirot, E.1
Pertuiset, E.2
Sordet, C.3
-
34
-
-
79954524343
-
Malignancies after rituximab treatment: Just coincidence or more?
-
Aksoy S, Arslan C, Harputluoglu H, Dizdar O, Altundag K. Malignancies after rituximab treatment: just coincidence or more? J. BUON 16(1), 112-115 (2011).
-
(2011)
J. BUON
, vol.16
, Issue.1
, pp. 112-115
-
-
Aksoy, S.1
Arslan, C.2
Harputluoglu, H.3
Dizdar, O.4
Altundag, K.5
-
35
-
-
83855160892
-
Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy
-
Coppola N, Pisaturo M, Guastaferro S et al. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Dig. Liver Dis. 44(1), 49-54 (2012).
-
(2012)
Dig. Liver Dis.
, vol.44
, Issue.1
, pp. 49-54
-
-
Coppola, N.1
Pisaturo, M.2
Guastaferro, S.3
-
36
-
-
80052777262
-
Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis
-
Clifford DB, Ances B, Costello C et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch. Neurol. 68(9), 1156-1164 (2011).
-
(2011)
Arch. Neurol.
, vol.68
, Issue.9
, pp. 1156-1164
-
-
Clifford, D.B.1
Ances, B.2
Costello, C.3
-
37
-
-
77950337482
-
Rituximab-associated infections
-
Gea-Banacloche JC. Rituximab-associated infections. Semin. Hematol. 47(2), 187-198 (2010).
-
(2010)
Semin. Hematol.
, vol.47
, Issue.2
, pp. 187-198
-
-
Gea-Banacloche, J.C.1
-
38
-
-
79961111815
-
Late-onset neutropenia following rituximab therapy in rheumatic diseases: Association with B lymphocyte depletion and infections
-
Tesfa D, Ajeganova S, Hagglund H et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 63(8), 2209-2214 (2011).
-
(2011)
Arthritis Rheum.
, vol.63
, Issue.8
, pp. 2209-2214
-
-
Tesfa, D.1
Ajeganova, S.2
Hagglund, H.3
-
39
-
-
77957275541
-
Late-onset neutropenia after rituximab treatment: Case series and comprehensive review of the literature
-
Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Med. (Baltimore) 89(5), 308-318 (2010).
-
(2010)
Med. (Baltimore)
, vol.89
, Issue.5
, pp. 308-318
-
-
Wolach, O.1
Bairey, O.2
Lahav, M.3
-
40
-
-
64549108014
-
Rituximab-associated acute thrombocytopenia: An under-diagnosed phenomenon
-
Ram R, Bonstein L, Gafter-Gvili A, Ben-Bassat I, Shpilberg O, Raanani P. Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon. Am. J. Hematol. 84(4), 247-250 (2009).
-
(2009)
Am. J. Hematol.
, vol.84
, Issue.4
, pp. 247-250
-
-
Ram, R.1
Bonstein, L.2
Gafter-Gvili, A.3
Ben-Bassat, I.4
Shpilberg, O.5
Raanani, P.6
-
41
-
-
69949148371
-
Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis
-
Kerekes G, Soltesz P, Der H et al. Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis. Ann. NY Acad. Sci. 1173, 814-821 (2009).
-
(2009)
Ann. NY Acad. Sci.
, vol.1173
, pp. 814-821
-
-
Kerekes, G.1
Soltesz Der P, H.2
-
42
-
-
72449136292
-
Insights into the heterogeneity of human B cells: Diverse functions, roles in autoimmunity, and use as therapeutic targets
-
doi:10.1007/s12026-009-8096-7 2009 Epub ahead of print
-
Anolik JH, Looney RJ, Lund FE, Randall TD, Sanz I. Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol. Res. doi:10.1007/s12026-009-8096-7 (2009) (Epub ahead of print).
-
Immunol. Res
-
-
Anolik, J.H.1
Looney, R.J.2
Lund, F.E.3
Randall, T.D.4
Sanz, I.5
-
43
-
-
72449140060
-
Novel human transitional B cell populations revealed by B cell depletion therapy
-
Palanichamy A, Barnard J, Zheng B et al. Novel human transitional B cell populations revealed by B cell depletion therapy. J. Immunol. 182(10), 5982-5993 (2009).
-
(2009)
J. Immunol.
, vol.182
, Issue.10
, pp. 5982-5993
-
-
Palanichamy, A.1
Barnard, J.2
Zheng, B.3
-
44
-
-
59949089567
-
Serum BLyS levels increase after rituximab as initial therapy in patients with follicular Grade 1 non-Hodgkin lymphoma
-
Ansell SM, Novak AJ, Ziesmer S et al. Serum BLyS levels increase after rituximab as initial therapy in patients with follicular Grade 1 non-Hodgkin lymphoma. Am. J. Hematol. 84(2), 71-73 (2009).
-
(2009)
Am. J. Hematol.
, vol.84
, Issue.2
, pp. 71-73
-
-
Ansell, S.M.1
Novak, A.J.2
Ziesmer, S.3
-
45
-
-
33947118656
-
Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis
-
DOI 10.1016/j.clim.2006.12.006, PII S1521661606009946
-
Sfkakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN. Theoflopoulos AN. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin. Immunol. 123(1), 66-73 (2007). (Pubitemid 46401511)
-
(2007)
Clinical Immunology
, vol.123
, Issue.1
, pp. 66-73
-
-
Sfikakis, P.P.1
Souliotis, V.L.2
Fragiadaki, K.G.3
Moutsopoulos, H.M.4
Boletis, J.N.5
Theofilopoulos, A.N.6
-
46
-
-
59249101969
-
Protein biochip array technology to monitor rituximab in rheumatoid arthritis
-
Fabre S, Guisset C, Tatem L et al. Protein biochip array technology to monitor rituximab in rheumatoid arthritis. Clin. Exp. Immunol. 155(3), 395-402 (2009).
-
(2009)
Clin. Exp. Immunol.
, vol.155
, Issue.3
, pp. 395-402
-
-
Fabre, S.1
Guisset, C.2
Tatem, L.3
|